LAGIPRA peptide (TFA)

LAGIPRA peptide TFA is a long-acting GIP1R agonist. LAGIPRA peptide TFA enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide TFA has the potential for the research of type 2 diabetes[1].

Product Specifications

Product Name Alternative

Long acting GIPRA-1 (TFA)

UNSPSC

12352209

Target

Insulin Receptor

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Purity

98.20

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C([C@@H](N)CC1=CC=C(O)C=C1)NC(C)(C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CCC(N)=O)=O)[C@@H](C)O)=O)[C@H](CC)C)=O)CC(N)=O)=O)CC2=CNC=N2)=O)CCCCN)=O)CC3=CNC4=CC=CC=C34)=O)CC(O)=O)=O)CC(N)=O)=O)CCCCN)=O)CCCCN)=O)=O)CCCCN)=O)CCC(N)=O)=O)C)=O)CC(C)C)=O)CC(C)C)=O)CC5=CNC6=CC=CC=C56)=O)CC(N)=O)=O)C(C)C)=O)CC7=CC=CC=C7)=O)CC(O)=O)=O)CCC(N)=O)=O)CCC(N)=O)=O)CC8=CNC=N8)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)=O)CCCCN)=O)CC(O)=O)=O)CCSC)=O)C)=O)[C@H](CC)C)=O)CO)=O)CC9=CC=C(O)C=C9)=O)CC(O)=O)=O)CO)=O)[C@H](CC)C)=O)CC%10=CC=CC=C%10)=O)[C@@H](C)O)=O)=O)CCC(O)=O)=O)C.O=C(O)C(F)(F)F.[x]

Molecular Formula

C264H406N64O78S.xC2HF3O2

Molecular Weight

5756.50 (free base)

References & Citations

[1]Samms RJ, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest. 2021 Jun 15;131 (12) :e146353.